Has Anna Kissin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,880 in general payments to Anna Kissin, MD across 981 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anna Kissin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anna Kissin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anna Kissin, MD

Endocrinology, Diabetes & Metabolism · Florham Park, NJNPI 1336254762

Payments from drug & device makers

$13,880in general payments, 2019–2025

Across 981 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$3K
Lilly USA, LLC$1K
Amgen$995
Abbott$805
Boehringer Ingelheim$661
Sanofi-aventis U.S. LLC$512
plus $6K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	265	$2,995
Lilly USA, LLC	103	$1,388
Amgen	76	$995
Abbott	32	$805
Boehringer Ingelheim	43	$661
Sanofi-aventis U.S. LLC	35	$512
Amneal Pharmaceuticals LLC	26	$400
AstraZeneca(2 entities)	26	$383
Merck	27	$383
AbbVie	34	$377
Pfizer	23	$346
Dexcom, Inc.	17	$324
IBSA Pharma Inc.	23	$315
Insulet Corporation	21	$275
Vivus LLC	18	$259
Bayer	13	$246
Mannkind Corporation	11	$236
Xeris Pharmaceuticals, Inc.	14	$217
Antares Pharma, Inc.	12	$161
Medtronic(2 entities)	9	$152
Novartis	7	$134
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	8	$121
Corcept Therapeutics	7	$115
Verity Pharmaceuticals Inc.	7	$115
Radius Health, Inc.	7	$106
Ipsen Biopharmaceuticals, Inc	6	$102
Currax Pharmaceuticals LLC	6	$88
Tandem Diabetes Care, Inc.	4	$86
Recordati_rare_diseases_inc.	5	$81
Tolmar, Inc.	5	$78
Madrigal Pharmaceuticals	3	$77
Kowa Pharmaceuticals America, Inc.	5	$71
Eisai Inc.	5	$69
Ascendis Pharma Endocrinology Inc	4	$68
GSK	5	$64
Ascensia Diabetes Care US Inc.	2	$64
BETA Bionics, Inc.	3	$62
Esperion Therapeutics, Inc.	4	$59
Ultragenyx Pharmaceutical Inc.	4	$56
Amryt Pharma Holdings Ltd	4	$55
Embecta Corp.	4	$54
Neurocrine Biosciences, Inc.	3	$51
Astellas Pharma US Inc	3	$50
Arbor Pharmaceuticals, Inc.	3	$44
Amphastar Pharmaceuticals, Inc.	3	$42
Acerus Pharmaceuticals Corporation	3	$42
Azurity Pharmaceuticals, Inc.	3	$42
Johnson & Johnson	3	$41
Bausch Health US, LLC	2	$38
Sequel Med Tech, LLC	2	$35
Averitas Pharma Inc.	2	$33
Idorsia Pharmaceuticals US Inc	2	$31
Takeda Pharmaceuticals U.S.A., Inc.	2	$29
Cequr Corporation	2	$29
Endo Pharmaceuticals Inc.	2	$28
Amarin Pharma, Inc.	2	$26
Zealand Pharma US, Inc.	2	$26
Chiesi USA, Inc.	1	$24
Intra-sana Laboratories	1	$18
Clarus Therapeutics Inc.	1	$15

How this compares

$13,880 in reported general payments places this provider in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey →

Medicare billing

Part B allowed, 2024

$203,308

Medicare patients

715

Services billed

2,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Florham Park

Sheera SiegelFlorham Park$12K
Barry GertzRahway$903K
Nawras MakhsidaRandolph$882K
Marc SandbergFlemington$567K
Joanne WaldstreicherNew Brunswick$441K
Gregory BaroneCherry Hill$433K
Taher ModarressiPennington$414K
Navtika DesaiHillsborough$408K
Atara SchultzTeaneck$357K
Anthony CannonTurnersville$296K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →